Theramex
Theramex is a pharmaceutical company based in London which produces women's health products focusing on contraception, fertility, menopause and osteoporosis.
| Industry | Pharmaceuticals |
|---|---|
| Headquarters | London, United Kingdom |
| Website | theramex |
It was established in 2018 with the acquisition of some of the assets of Teva Active Pharmaceutical Ingredients relating to Theramex Laboratories, a pharmaceutical company which was based in Monaco. Brands include Ovaleap, Zoely, Seasonique, Actonel, Estreva and Lutenyl.[1]
Anish Mehta is the chief executive.
In the latter part of 2018 there were problems with the production of its hormone replacement therapy products Evorel, FemSeven Conti and FemSeven Sequi.[2] These Hormone replacement therapy patches were not available because of issues manufacturing the glue for the patches in China.[3] The company recruited another manufacturer to assist with supply in December 2019. [4] It is not expected that normal supplies will be available before June 2020.[5]
It made an agreement with TherapeuticsMD in 2019 for exclusive licensing and supply rights to Bijuva and Imvexxy outside of the USA, Canada and Israel for which it paid a license fee of $15.5 million.[6]
References
- "New pharma company dedicated to women and their health launches". European Pharmaceutical Manufacturer. 5 February 2018. Retrieved 23 February 2020.
- "Shortage of HRTs FemSeven Conti and Sequi to continue until 2020". Chemist & Druggist. 30 April 2019. Retrieved 23 February 2020.
- "HRT drugs rationed amid UK shortage set to last for months". Telegraph. 24 August 2019. Retrieved 23 February 2020.
- "HRT products to return earlier than expected". Pharmaceutical Journal. 11 December 2019. Retrieved 23 February 2020.
- "The HRT crisis that forces women to buy online". Telegraph. 11 February 2020. Retrieved 23 February 2020.
- "Is TherapeuticsMD Stock a Buy?". The Motley Fool. 13 February 2020. Retrieved 23 February 2020.